TAB2-C6ORF162 Fusion FISH Probe
The TAB2-C6ORF162 Fusion FISH Probe is used to confirm a fusion of the TAB2 and C6ORF162 genes. The fusion of the TAB2 and C6ORF162 genes has been associated with Prostate Adenocarcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use. Please note that both genes fall on the same chromosome and inter-chromosomal detection may be difficult to detect depending on the genes proximity to one another. Please consult our support staff before ordering this product to ensure that the probe can be designed to meet your specific needs.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| TAB2-C6ORF162-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-RERE | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-REOR | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-REGO | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-REGR | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-OROR | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-GORE | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-GROR | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| TAB2-C6ORF162-20-AQAQ | 20 (40 μL) | 200 μL |
|
TAB2 Gene Summary
The protein encoded by this gene is an activator of MAP3K7/TAK1, which is required for for the IL-1 induced activation of nuclear factor kappaB and MAPK8/JNK. This protein forms a kinase complex with TRAF6, MAP3K7 and TAB1, and it thus serves as an adaptor that links MAP3K7 and TRAF6. This protein, along with TAB1 and MAP3K7, also participates in the signal transduction induced by TNFSF11/RANKl through the activation of the receptor activator of NF-kappaB (TNFRSF11A/RANK), which may regulate the development and function of osteoclasts. Studies of the related mouse protein indicate that it functions to protect against liver damage caused by chemical stressors. Mutations in this gene cause congenital heart defects, multiple types, 2 (CHTD2). Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2014]
Gene Name: TGF-beta Activated Kinase 1/MAP3K7 Binding Protein 2
Chromosome: CHR6: 149639435 -149732747
Locus: 6q25.1
Gene Diseases
The TAB2 C6ORF162 Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Prostate Adenocarcinoma |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|